The company was listed separately on October 19, following its demerger from Piramal Enterprises
In a Q&A, Nandini Piramal, chairperson of the firm, says the company currently sees great scope in expanding and organically growing the OTC business, and wants to build more consumer focused brands
Domestic brokerage Motilal Oswal has set a price target of Rs 210 for the stock
In October 2021, the board of directors of Piramal Enterprises (PEL) had approved the demerger of the pharmaceuticals business, and simplification of the corporate structure